J&J, Arrowhead partner on gene-silencing drug

Oct 04, 2018

Johnson & Johnson’s Janssen Pharmaceuticals has entered into an agreement with Arrowhead Pharmaceuticals for an exclusive, worldwide license to develop and commercialize a therapy candidate being investigated for the treatment of chronic hepatitis B viral infection.

A new frontier in the field of medicine, the gene-silencing class of drugs employs a principle known as RNA interference to block activity of a rogue gene.

Under the deal, Janssen will obtain a worldwide license for California-based Arrowhead’s ARO-HBV drug and an option to collaborate on up to three new RNA interference (RNAi) drugs, which use gene-silencing technology.

Read the press release

Don't miss your Daily Dose! Subscribe to the daily eNewsletter

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments